In the context of new anti-obesity medications, the American College of Cardiology has issued a Scientific Statement updating ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

A federal judge in Texas has upheld the FDA’s decision to remove GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, from its drug shortage list, rejecting a bid by compounding pharmacies to ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

aMedical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China bState Key Laboratory of Digestive Disease, ...

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 ...

Use of growth hormone (GH) for the treatment of adult-onset craniopharyngioma does not lower risk for liver disease, according to results of a study published in the Journal of the Endocrine Society.

Strong outcomes were seen in terms of weight loss, with lower doses of semaglutide used. HealthDay News — Weight loss treatment combining personalized semaglutide with intensive behavioral therapy ...